Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir for CMV infection in HSCT recipients intolerant or contraindicated to standard antivirals
2025-521074-34-00Phase 2Authorised
- Sponsor
- GITMO
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maribavir in cytomegalovirus disease (CMV), sponsored by GITMO. Primary endpoints: Virologic response at 8 weeks and Treatment-discontinuation side effects. Planned start Nov 2025; status: authorised.
02
Drugs
maribavir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2025-521074-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521074-34-00.